Page last updated: 2024-11-04

sulfamethizole and Leukemia, Myelogenous, Chronic, BCR-ABL Positive

sulfamethizole has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 1 studies

Sulfamethizole: A sulfathiazole antibacterial agent.
sulfamethizole : A sulfonamide consisting of a 1,3,4-thiadiazole nucleus with a methyl substituent at C-5 and a 4-aminobenzenesulfonamido group at C-2.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive: Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bartoloni, A1
Fanci, R1
Orsi, A1
Aquilini, D1
Bosi, A1
Rossi Ferrini, P1
Paradisi, F1

Trials

1 trial available for sulfamethizole and Leukemia, Myelogenous, Chronic, BCR-ABL Positive

ArticleYear
The influence of ofloxacin versus trimethoprim-sulfamethoxazole on the aerobic flora in granulocytopenic subjects.
    Journal of chemotherapy (Florence, Italy), 1989, Volume: 1, Issue:2

    Topics: Adult; Aged; Agranulocytosis; Bacteria, Aerobic; Drug Combinations; Female; Humans; Intestines; Leuk

1989